CXCL12 and neoplasm: However, in vivo, CXCL12 ligand may be expressed at higher levels than those observed in cell cultures[32, 33] and small molecular competitive inhibitors of CXCR7, such as antagonists of SDF-1a binding have been shown to decrease tumor growth in lymphoma and lung carcinoma[1].